{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,3]],"date-time":"2026-03-03T04:23:23Z","timestamp":1772511803379,"version":"3.50.1"},"reference-count":18,"publisher":"Japanese Society for Hygiene","issue":"0","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Environ Health Prev Med","Environ. Health Prev. Med."],"published-print":{"date-parts":[[2024]]},"DOI":"10.1265\/ehpm.24-00158","type":"journal-article","created":{"date-parts":[[2024,8,27]],"date-time":"2024-08-27T22:11:22Z","timestamp":1724796682000},"page":"44-44","source":"Crossref","is-referenced-by-count":2,"title":["Quality of life and neurological symptoms in patients with neurofibromatosis type 2: a national database study in Japan"],"prefix":"10.1265","volume":"29","author":[{"given":"Takashi","family":"Yamauchi","sequence":"first","affiliation":[{"name":"Department of Public Health and Environmental Medicine, The Jikei University School of Medicine"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8392-1870","authenticated-orcid":false,"given":"Machi","family":"Suka","sequence":"additional","affiliation":[{"name":"Department of Public Health and Environmental Medicine, The Jikei University School of Medicine"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"335","reference":[{"key":"1","doi-asserted-by":"crossref","unstructured":"1. Asthagiri AR, Parry DM, Butman JA, Kim HJ, Tsilou ET, Zhuang Z, et al. Neurofibromatosis type 2. Lancet. 2009;373:1974\u201386.","DOI":"10.1016\/S0140-6736(09)60259-2"},{"key":"2","doi-asserted-by":"crossref","unstructured":"2. Evans DG. Neurofibromatosis type 2 (NF2): a clinical and molecular review. Orphanet J Rare Dis. 2009;4:16.","DOI":"10.1186\/1750-1172-4-16"},{"key":"3","unstructured":"3. Evans DG, Huson SM, Donnai D, Neary W, Blair V, Newton V, et al. A clinical study of type 2 neurofibromatosis. Q J Med. 1992;84:603\u201318."},{"key":"4","doi-asserted-by":"crossref","unstructured":"4. Vranceanu AM, Merker VL, Park E, Plotkin SR. Quality of life among adult patients with neurofibromatosis 1, neurofibromatosis 2 and schwannomatosis: a systematic review of the literature. J Neurooncol. 2013;114:257\u201362.","DOI":"10.1007\/s11060-013-1195-2"},{"key":"5","doi-asserted-by":"crossref","unstructured":"5. Sanagoo A, Jouybari L, Koohi F, Sayehmiri F. Evaluation of QoL in neurofibromatosis patients: a systematic review and meta-analysis study. BMC Neurol. 2019;19:123.","DOI":"10.1186\/s12883-019-1338-y"},{"key":"6","doi-asserted-by":"crossref","unstructured":"6. Neary WJ, Hillier VF, Flute T, Stephens SD, Ramsden RT, Evans DG. The relationship between patients\u2019 perception of the effects of neurofibromatosis type 2 and the domains of the Short Form-36. Clin Otolaryngol. 2010;35:291\u20139.","DOI":"10.1111\/j.1749-4486.2010.02176.x"},{"key":"7","doi-asserted-by":"crossref","unstructured":"7. Kanatani Y, Tomita N, Sato Y, Eto A, Omoe H, Mizushima H. National registry of designated intractable diseases in Japan: present status and future prospects. Neurol Med Chir (Tokyo). 2017;57:1\u20137.","DOI":"10.2176\/nmc.st.2016-0135"},{"key":"8","doi-asserted-by":"crossref","unstructured":"8. Yamauchi T, Suka M, Nishigori C, Yanagisawa H. Evaluation of neurofibromatosis type 1 progression using a nationwide registry of patients who submitted claims for medical expense subsidies in Japan between 2008 and 2012. Orphanet J Rare Dis. 2019;14:166.","DOI":"10.1186\/s13023-019-1148-8"},{"key":"9","unstructured":"9. Japan Intractable Diseases Information Center: Japan Intractable Diseases Information Center [in Japanese]. http:\/\/www.nanbyou.or.jp\/. Accessed June 6, 2024."},{"key":"10","doi-asserted-by":"crossref","unstructured":"10. Okoshi H, Yamauchi T, Suka M, Saito K, Nishigori C, Yanagisawa H. Social independence of patients with neurofibromatosis type 2 in Japan: analysis of a national registry of patients receiving medical expense subsidies, 2004\u20132013. Neurol Med Chir (Tokyo). 2020;60:450\u20137.","DOI":"10.2176\/nmc.oa.2020-0106"},{"key":"11","doi-asserted-by":"crossref","unstructured":"11. Okoshi H, Yamauchi T, Suka M, Yanagisawa H, Fujii M, Nishigori C. Loss of social independence in patients with neurofibromatosis type 2: a follow-up study using a national registry in Japan. Environ Health Prev Med. 2023;28:46.","DOI":"10.1265\/ehpm.22-00222"},{"key":"12","doi-asserted-by":"crossref","unstructured":"12. Iwatate K, Yokoo T, Iwatate E, Ichikawa M, Sato T, Fujii M, et al. Population Characteristics and Progressive Disability in Neurofibromatosis Type 2. World Neurosurg. 2017;106:653\u201360.","DOI":"10.1016\/j.wneu.2017.07.036"},{"key":"13","doi-asserted-by":"crossref","unstructured":"13. Yamauchi T, Suka M. Quality of life in patients with neurofibromatosis type 1: a nationwide database study in Japan from 2015 to 2019. Environ Health Prev Med. 2023;28:77.","DOI":"10.1265\/ehpm.23-00221"},{"key":"14","doi-asserted-by":"crossref","unstructured":"14. National Institute of Health Consensus Development Conference. Neurofibromatosis Conference Statement. Arch Neurol. 1988;45:575\u20138.","DOI":"10.1001\/archneur.1988.00520290115023"},{"key":"15","doi-asserted-by":"crossref","unstructured":"15. Matsuo M, Ohno K, Ohtsuka F. Characterization of early onset neurofibromatosis type 2. Brain Dev. 2014;36:148\u201352.","DOI":"10.1016\/j.braindev.2013.01.007"},{"key":"16","doi-asserted-by":"crossref","unstructured":"16. Aboukais R, Baroncini M, Zairi F, Bonne NX, Schapira S, Vincent C, et al. Prognostic value and management of spinal tumors in neurofibromatosis type 2 patients. Acta Neurochir (Wien). 2013;155:771\u20137.","DOI":"10.1007\/s00701-012-1590-z"},{"key":"17","doi-asserted-by":"crossref","unstructured":"17. Wang DL, Smith KB, Esparza S, Leigh FA, Muzikansky A, Park ER, et al. Emotional functioning of patients with neurofibromatosis tumor suppressor syndrome. Genet Med. 2012;14:977\u201382.","DOI":"10.1038\/gim.2012.85"},{"key":"18","doi-asserted-by":"crossref","unstructured":"18. Yoshida Y, Ehara Y, Koga M, Imafuku S. Health-related quality of life in patients with neurofibromatosis 1 in Japan: A questionnaire survey using EQ-5D-5L. J Dermatol. 2022;49:1228\u201332.","DOI":"10.1111\/1346-8138.16510"}],"container-title":["Environmental Health and Preventive Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.jstage.jst.go.jp\/article\/ehpm\/29\/0\/29_24-00158\/_pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,8,31]],"date-time":"2024-08-31T05:03:15Z","timestamp":1725080595000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.jstage.jst.go.jp\/article\/ehpm\/29\/0\/29_24-00158\/_article"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024]]},"references-count":18,"journal-issue":{"issue":"0","published-print":{"date-parts":[[2024]]}},"URL":"https:\/\/doi.org\/10.1265\/ehpm.24-00158","relation":{},"ISSN":["1342-078X","1347-4715"],"issn-type":[{"value":"1342-078X","type":"print"},{"value":"1347-4715","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024]]},"article-number":"24-00158"}}